Job alert: Allergios is looking for a Scientific Project Manager

Did you know?

  • Allergy is among the world’s most common chronic diseases
  • 20% of the world population suffers from an allergy
  • Current test methods (particularly for food allergy) are not sufficient for an unambiguous allergy diagnosis

Allergios’® direct allergy test enables patients to be better diagnosed and effectively treated

The Challenge

Allergy is among the most common chronic diseases worldwide. Up to 20% of patients with allergies live with a severe debilitating form of their condition, and struggle daily with the fear of a possible asthma attack, anaphylactic shock, or even death from an allergic reaction (EAACI, 2016).

Current tests to diagnose especially the largely rising food allergy require cumbersome methodologies that are risky for thepatients (ingesting the potential allergen), difficult to perform for th medical doctors, and costly thourgh complex procedures and late diagnosis.

Our Solution

Based on an invention of Researchers from the University of Bremen, supported by colleagues at the Medical University of Vienna, Allergios® has developed a method and system that can directly diagnose allergies by visualizing the allergic response: the ability of immunological factors in patient blood to induce degranulation of basophils in the presence of allergen Allergios® offers an effective and scalable In – vitro allergy diagnostic, which works by visually analyzing how a few drops of blood serum enable allergen-specific degranulation of basophil cells. Armed with a disposable microfluidic chip, an optical reader (GranulEye®) and AI based analysis software, allergy tests can be run safely and easily, enabling clinicians to provide timely effective treatment options based on a clear and unambiguous diagnosis by the Allergios® allergy test. Allergios will initially focus on Food Allergies (replacing the Food Challenge test) and then gradually expand to other IgE-mediated allergies. Allergios®– We see allergy.

We see Allergy

Our Core Team

Dr. Holger Engel

CEO

vacancy

Scientific Project Manager

Sergi Chavalés

Biomedical Engineer R&D

Advisory Board

Prof. Dr. Heimo Breiteneder

World-renowned expert on the molecular biology of allergens

Inventor

Dr. Christine Hafner

Clinical allergist and dermatologist with a focus on molecular allergy diagnostics

Inventor

Dr. Claas Falldorf

BIAS Germany

Inventor

Gina Melchner

NLC

Venture Partner

Company update

Following a strategic reset in Q2/2025, operational leadership has been realigned under Holger Engel as new CEO, re-building a team with the required diagnostics expertise.
The immediate focus is on transforming the technology prototype into a fully validated diagnostic platform, building on our awarded Health Holland Grant funding, and an extension of our seed financing in HY2-2025 and targeting a Series A round in mid 2026.

News

Automated, label-free allergy diagnostics platform in development

Prototype 2.0 in Development – Strategic Update from Allergios

In July 2025, Dr. Holger Engel was appointed as CEO of Allergios to realign the company’s development efforts and prepare the platform for clinical applicability. The objective is clear: develop a robust, automatable version of the GranulEye® prototype to enable functional, cell-based allergy diagnostics in routine clinical settings. Since then,...

Allergios news

Allergios is awarded HealthHolland grant funding, recognition of the relevance of our innovative IVD test for food allergies

Allergios is proud to announce a public-private-partnership with Wageningen University & Research, supported by Health-Holland, Top Sector Life Sciences & Health. The objective of this partnership is to validate an innovative test for the diagnosis of food allergy, the GranulEye test. Dr. ir. Janneke Ruinemans-Koerts (clinical chemist at Rijnstate Hospital/Dicoon...

Join our team

We are currently looking for

Scientific Project Manager

Contact us

"*" indicates required fields